Wendy Barclay

List of Publications by Year in Descending Order

213 papers	8,360 citations	48 h-index	85 g-index
247 ext. papers	12,881 ext. citations	12.8 avg, IF	6.53 L-index

#	Paper	IF	Citations
213	SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys.. *Lancet Respiratory Medicine,the*, **2022**,	35.1	7
212	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.. *Cell*, **2022**,	56.2	154
211	Mutations that adapt SARS-CoV-2 to mink or ferret do not increase fitness in the human airway.. *Cell Reports*, **2022**, 110344	10.6	10
210	A common TMPRSS2 variant has a protective effect against severe COVID-19.. *Current Research in Translational Medicine*, **2022**, 70, 103333	3.7	4
209	Rapid increase in Omicron infections in England during December 2021: REACT-1 study.. *Science*, **2022**, 375, eabn8347	33.3	11
208	Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection.. *Nature Immunology*, **2022**, 23, 40-49	19.1	22
207	Naïve Human Macrophages Are Refractory to SARS-CoV-2 Infection and Exhibit a Modest Inflammatory Response Early in Infection.. *Viruses*, **2022**, 14,	6.2	4
206	Population antibody responses following COVID-19 vaccination in 212,102 individuals.. *Nature Communications*, **2022**, 13, 907	17.4	8
205	Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.. *Nature Medicine*, **2022**,	50.5	23
204	Ultrastructural insight into SARS-CoV-2 entry and budding in human airway epithelium.. *Nature Communications*, **2022**, 13, 1609	17.4	3
203	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies.. *EBioMedicine*, **2022**, 77, 103902	8.8	5
202	SARS-CoV-2 variants of concern alpha, beta, gamma and delta have extended ACE2 receptor host ranges.. *Journal of General Virology*, **2022**, 103,	4.9	2
201	Breakthrough SARS-CoV-2 infections in double and triple vaccinated adults and single dose vaccine effectiveness among children in Autumn 2021 in England: REACT-1 study.. *EClinicalMedicine*, **2022**, 48, 101419	11.3	0
200	Investigating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Surface and Air Contamination in an Acute Healthcare Setting During the Peak of the Coronavirus Disease 2019 (COVID-19) Pandemic in London. *Clinical Infectious Diseases*, **2021**, 73, e1870-e1877	11.6	126
199	Context-specific emergence and growth of the SARS-CoV-2 Delta variant. **2021**,		3
198	SARS-CoV-2 environmental contamination from hospitalised patients with COVID-19 receiving aerosol-generating procedures. *Thorax*, **2021**,	7.3	3
197	Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. *Science*, **2021**, 374, eabl9551	33.3	31

196	Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. *PLoS Pathogens*, **2021**, 17, e1010022	7.6	35
195	Acceptability, Usability, and Performance of Lateral Flow Immunoassay Tests for Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: REACT-2 Study of Self-Testing in Nonhealthcare Key Workers. *Open Forum Infectious Diseases*, **2021**, 8, ofab496	1	3
194	Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. *Lancet Infectious Diseases, The*, **2021**,	25.5	150
193	Host Cell Factors That Interact with Influenza Virus Ribonucleoproteins. *Cold Spring Harbor Perspectives in Medicine*, **2021**, 11,	5.4	4
192	SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study. *BMJ, The*, **2021**, 372, n423	5.9	24
191	Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. *Lancet, The*, **2021**, 397, 1178-1181	40	171
190	The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. *Nature Microbiology*, **2021**, 6, 899-909	26.6	206
189	Resurgence of SARS-CoV-2: Detection by community viral surveillance. *Science*, **2021**, 372, 990-995	33.3	36
188	Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia. *Nature*, **2021**, 594, 88-93	50.4	103
187	SARS-CoV-2 one year on: evidence for ongoing viral adaptation. *Journal of General Virology*, **2021**, 102,	4.9	63
186	Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults. *Lancet Regional Health - Europe, The*, **2021**, 4, 100098		46
185	Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model. *PLoS Pathogens*, **2021**, 17, e1009527	7.6	7
184	Favipiravir-resistant influenza A virus shows potential for transmission. *PLoS Pathogens*, **2021**, 17, e1008937	7.6	6
183	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. *Lancet, The*, **2021**, 398, 223-237	40	39
182	Usability and Acceptability of Home-based Self-testing for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies for Population Surveillance. *Clinical Infectious Diseases*, **2021**, 72, e384-e393	11.6	34
181	SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. *Nature Communications*, **2021**, 12, 905	17.4	80
180	The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells. *Nature Communications*, **2021**, 12, 4068	17.4	21
179	2020 Hindsight: Should evolutionary virologists have expected the unexpected during a pandemic?. *Evolution; International Journal of Organic Evolution*, **2021**, 75, 2311-2316	3.8	4

178	Inactivation of SARS-CoV-2 in chlorinated swimming pool water. *Water Research*, **2021**, 205, 117718	12.5	7
177	A natural variant in ANP32B impairs influenza virus replication in human cells. *Journal of General Virology*, **2021**, 102,	4.9	3
176	The origins of SARS-CoV-2: A critical review. *Cell*, **2021**, 184, 4848-4856	56.2	103
175	SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. *Nature*, **2021**, 599, 114-119	50.4	334
174	A prenylated dsRNA sensor protects against severe COVID-19. *Science*, **2021**, 374, eabj3624	33.3	26
173	Handheld Point-of-Care System for Rapid Detection of SARS-CoV-2 Extracted RNA in under 20 min. *ACS Central Science*, **2021**, 7, 307-317	16.8	43
172	Context-specific emergence and growth of the SARS-CoV-2 Delta variant. **2021**,		2
171	Quantifying mechanistic traits of influenza viral dynamics using in vitro data. *Epidemics*, **2020**, 33, 100406	3.1	1
170	Population implications of the deployment of novel universal vaccines against epidemic and pandemic influenza. *Journal of the Royal Society Interface*, **2020**, 17, 20190879	4.1	5
169	Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. *Nature Communications*, **2020**, 11, 3523	17.4	216
168	Characterising viable virus from air exhaled by H1N1 influenza-infected ferrets reveals the importance of haemagglutinin stability for airborne infectivity. *PLoS Pathogens*, **2020**, 16, e1008362	7.6	12
167	Swine ANP32A Supports Avian Influenza Virus Polymerase. *Journal of Virology*, **2020**, 94,	6.6	11
166	Elucidating the Interactions between Influenza Virus Polymerase and Host Factor ANP32A. *Journal of Virology*, **2020**, 94,	6.6	15
165	REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol. *Wellcome Open Research*, **2020**, 5, 200	4.8	51
164	Passage of influenza A/H3N2 viruses in human airway cells removes artefactual variants associated with neuraminidase-mediated binding. *Journal of General Virology*, **2020**, 101, 456-466	4.9	6
163	The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. *Journal of General Virology*, **2020**, 101, 791-797	4.9	211
162	Ultrastructure of cell trafficking pathways and coronavirus: how to recognise the wolf amongst the sheep. *Journal of Pathology*, **2020**, 252, 346-357	9.4	6
161	Host ANP32A mediates the assembly of the influenza virus replicase. *Nature*, **2020**, 587, 638-643	50.4	25

160	Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey. *Thorax*, **2020**, 75, 1082-1088	7.3	85
159	Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza. *PLoS Pathogens*, **2020**, 16, e1008716	7.6	5
158	Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study. *Lancet Microbe, The*, **2020**, 1, e300-e307	22.2	53
157	The Emergence of H7N7 Highly Pathogenic Avian Influenza Virus from Low Pathogenicity Avian Influenza Virus Using an Embryo Culture Model. *Viruses*, **2020**, 12,	6.2	3
156	Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. *Lancet Microbe, The*, **2020**, 1, e245-e253	22.2	270
155	REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol. *Wellcome Open Research*, **2020**, 5, 200	4.8	20
154	Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission. *PLoS Pathogens*, **2020**, 16, e1008395	7.6	15
153	Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission **2020**, 16, e1008395		
152	Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission **2020**, 16, e1008395		
151	Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission **2020**, 16, e1008395		
150	Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission **2020**, 16, e1008395		
149	Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza **2020**, 16, e1008716		
148	Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza **2020**, 16, e1008716		
147	Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza **2020**, 16, e1008716		
146	Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza **2020**, 16, e1008716		
145	Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza **2020**, 16, e1008716		
144	Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza **2020**, 16, e1008716		
143	Pregnancy-related immune suppression leads to altered influenza vaccine recall responses. *Clinical Immunology*, **2019**, 208, 108254	9	4

142	ANP32 Proteins Are Essential for Influenza Virus Replication in Human Cells. *Journal of Virology*, **2019**, 93,	6.6	32
141	Effect of a Russian-backbone live-attenuated influenza vaccine with an updated pandemic H1N1 strain on shedding and immunogenicity among children in The Gambia: an open-label, observational, phase 4 study. *Lancet Respiratory Medicine,the*, **2019**, 7, 665-676	35.1	18
140	Regulation of influenza A virus mRNA splicing by CLK1. *Antiviral Research*, **2019**, 168, 187-196	10.8	12
139	Influenza Virus with Increased pH of Hemagglutinin Activation Has Improved Replication in Cell Culture but at the Cost of Infectivity in Human Airway Epithelium. *Journal of Virology*, **2019**, 93,	6.6	16
138	RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals. *PLoS Pathogens*, **2019**, 15, e1007601	7.6	15
137	Entry of the bat influenza H17N10 virus into mammalian cells is enabled by the MHC class II HLA-DR receptor. *Nature Microbiology*, **2019**, 4, 2035-2038	26.6	19
136	Host Determinants of Influenza RNA Synthesis. *Annual Review of Virology*, **2019**, 6, 215-233	14.6	16
135	Species specific differences in use of ANP32 proteins by influenza A virus. *ELife*, **2019**, 8,	8.9	39
134	Host and viral determinants of influenza A virus species specificity. *Nature Reviews Microbiology*, **2019**, 17, 67-81	22.2	193
133	Determining the Mutation Bias of Favipiravir in Influenza Virus Using Next-Generation Sequencing. *Journal of Virology*, **2019**, 93,	6.6	31
132	Mouse Models of Influenza Infection with Circulating Strains to Test Seasonal Vaccine Efficacy. *Frontiers in Immunology*, **2018**, 9, 126	8.4	24
131	Assays to Measure the Activity of Influenza Virus Polymerase. *Methods in Molecular Biology*, **2018**, 1836, 343-374	1.4	12
130	Internal genes of a highly pathogenic H5N1 influenza virus determine high viral replication in myeloid cells and severe outcome of infection in mice. *PLoS Pathogens*, **2018**, 14, e1006821	7.6	19
129	Urgent challenges in implementing live attenuated influenza vaccine. *Lancet Infectious Diseases, The*, **2018**, 18, e25-e32	25.5	29
128	The mechanism of resistance to favipiravir in influenza. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 11613-11618	11.5	160
127	Ferrets as Models for Influenza Virus Transmission Studies and Pandemic Risk Assessments. *Emerging Infectious Diseases*, **2018**, 24, 965-971	10.2	36
126	Immune Escape Variants of H9N2 Influenza Viruses Containing Deletions at the Hemagglutinin Receptor Binding Site Retain Fitness and Display Enhanced Zoonotic Characteristics. *Journal of Virology*, **2017**, 91,	6.6	28
125	Variability in H9N2 haemagglutinin receptor-binding preference and the pH of fusion. *Emerging Microbes and Infections*, **2017**, 6, e11	18.9	31

124	Can defective interfering RNAs affect the live attenuated influenza vaccine? - AuthorsSreply. *Lancet Infectious Diseases, The*, **2017**, 17, 1235-1236	25.5	2
123	M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza. *JCI Insight*, **2017**, 2, e91868	9.9	39
122	Knowns and unknowns of influenza B viruses. *Future Microbiology*, **2016**, 11, 119-35	2.9	58
121	Species difference in ANP32A underlies influenza A virus polymerase host restriction. *Nature*, **2016**, 529, 101-4	50.4	154
120	Viral factors in influenza pandemic risk assessment. *ELife*, **2016**, 5,	8.9	61
119	NB protein does not affect influenza B virus replication in vitro and is not required for replication in or transmission between ferrets. *Journal of General Virology*, **2016**, 97, 593-601	4.9	7
118	An engineered avian-origin influenza A virus for pancreatic ductal adenocarcinoma virotherapy. *Journal of General Virology*, **2016**, 97, 2166-2179	4.9	9
117	Influenza A virus PB1-F2 protein prolongs viral shedding in chickens lengthening the transmission window. *Journal of General Virology*, **2016**, 97, 2516-2527	4.9	28
116	Antiviral Screening of Multiple Compounds against Ebola Virus. *Viruses*, **2016**, 8,	6.2	31
115	Computational and molecular analysis of conserved influenza A virus RNA secondary structures involved in infectious virion production. *RNA Biology*, **2016**, 13, 883-94	4.8	29
114	Contact transmission of influenza virus between ferrets imposes a looser bottleneck than respiratory droplet transmission allowing propagation of antiviral resistance. *Scientific Reports*, **2016**, 6, 29793	4.9	35
113	One-way trip: influenza virusSadaptation to gallinaceous poultry may limit its pandemic potential. *BioEssays*, **2015**, 37, 204-12	4.1	20
112	Amino acid substitution D222N from fatal influenza infection affects receptor-binding properties of the influenza A(H1N1)pdm09 virus. *Virology*, **2015**, 484, 15-21	3.6	10
111	Ferret airway epithelial cell cultures support efficient replication of influenza B virus but not mumps virus. *Journal of General Virology*, **2015**, 96, 2092-2098	4.9	4
110	The Functional Study of the N-Terminal Region of Influenza B Virus Nucleoprotein. *PLoS ONE*, **2015**, 10, e0137802	3.7	8
109	Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. *F1000Research*, **2015**, 4, 30	3.6	48
108	Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. *F1000Research*, **2015**, 4, 30	3.6	52
107	Accumulation of human-adapting mutations during circulation of A(H1N1)pdm09 influenza virus in humans in the United Kingdom. *Journal of Virology*, **2014**, 88, 13269-83	6.6	58

106	Low dose influenza virus challenge in the ferret leads to increased virus shedding and greater sensitivity to oseltamivir. *PLoS ONE*, **2014**, 9, e94090	3.7	37
105	Viral determinants of influenza A virus host range. *Journal of General Virology*, **2014**, 95, 1193-1210	4.9	104
104	Transfer of the amino-terminal nuclear envelope targeting domain of human MX2 converts MX1 into an HIV-1 resistance factor. *Journal of Virology*, **2014**, 88, 9017-26	6.6	61
103	Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease. *Mucosal Immunology*, **2014**, 7, 89-100	9.2	15
102	Glycomic characterization of respiratory tract tissues of ferrets: implications for its use in influenza virus infection studies. *Journal of Biological Chemistry*, **2014**, 289, 28489-504	5.4	65
101	The effect of the PB2 mutation 627K on highly pathogenic H5N1 avian influenza virus is dependent on the virus lineage. *Journal of Virology*, **2013**, 87, 9983-96	6.6	45
100	Cellular immune correlates of protection against symptomatic pandemic influenza. *Nature Medicine* , **2013**, 19, 1305-12	50.5	572
99	Investigation of influenza virus polymerase activity in pig cells. *Journal of Virology*, **2013**, 87, 384-94	6.6	35
98	Mutations in haemagglutinin that affect receptor binding and pH stability increase replication of a PR8 influenza virus with H5 HA in the upper respiratory tract of ferrets and may contribute to transmissibility. *Journal of General Virology*, **2013**, 94, 1220-1229	4.9	54
97	Transmission studies resume for avian flu. *Science*, **2013**, 339, 520-1	33.3	31
96	Unstable polymerase-nucleoprotein interaction is not responsible for avian influenza virus polymerase restriction in human cells. *Journal of Virology*, **2013**, 87, 1278-84	6.6	34
95	The short stalk length of highly pathogenic avian influenza H5N1 virus neuraminidase limits transmission of pandemic H1N1 virus in ferrets. *Journal of Virology*, **2013**, 87, 10539-51	6.6	58
94	Using Reverse Genetics to Improve Influenza Vaccines **2012**, 224-249		1
93	Transmission of a 2009 H1N1 pandemic influenza virus occurs before fever is detected, in the ferret model. *PLoS ONE*, **2012**, 7, e43303	3.7	31
92	Pause on avian flu transmission research. *Science*, **2012**, 335, 400-1	33.3	50
91	An influenza reassortant with polymerase of pH1N1 and NS gene of H3N2 influenza A virus is attenuated in vivo. *Journal of General Virology*, **2012**, 93, 998-1006	4.9	15
90	Influenza pandemics. *Advances in Experimental Medicine and Biology*, **2011**, 719, 81-103	3.6	11
89	Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines. *Journal of Virology*, **2011**, 85, 3010-4	6.6	33

88	Receptor binding profiles of avian influenza virus hemagglutinin subtypes on human cells as a predictor of pandemic potential. *Journal of Virology*, **2011**, 85, 1875-80	6.6	38
87	Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness. *Journal of Antimicrobial Chemotherapy*, **2011**, 66, 466-70	5.1	53
86	Lack of transmission of a human influenza virus with avian receptor specificity between ferrets is not due to decreased virus shedding but rather a lower infectivity in vivo. *Journal of General Virology*, **2011**, 92, 1822-1831	4.9	43
85	A single amino acid in the HA of pH1N1 2009 influenza virus affects cell tropism in human airway epithelium, but not transmission in ferrets. *PLoS ONE*, **2011**, 6, e25755	3.7	24
84	Evidence for avian and human host cell factors that affect the activity of influenza virus polymerase. *Journal of Virology*, **2010**, 84, 9978-86	6.6	81
83	RIG-I detects viral genomic RNA during negative-strand RNA virus infection. *Cell*, **2010**, 140, 397-408	56.2	429
82	Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs. *Vaccine*, **2010**, 28, 2973-9	4.1	9
81	Avian Influenza virus glycoproteins restrict virus replication and spread through human airway epithelium at temperatures of the proximal airways. *PLoS Pathogens*, **2009**, 5, e1000424	7.6	64
80	A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. *Vaccine*, **2009**, 27, 1889-97	4.1	125
79	A complicated message: Identification of a novel PB1-related protein translated from influenza A virus segment 2 mRNA. *Journal of Virology*, **2009**, 83, 8021-31	6.6	273
78	Mutations in H5N1 influenza virus hemagglutinin that confer binding to human tracheal airway epithelium. *PLoS ONE*, **2009**, 4, e7836	3.7	56
77	Development of a reverse genetics system enabling the rescue of recombinant avian influenza virus A/Turkey/England/50-92/91 (H5N1). *Avian Diseases*, **2007**, 51, 393-5	1.6	18
76	Alterations in receptor binding properties of recent human influenza H3N2 viruses are associated with reduced natural killer cell lysis of infected cells. *Journal of Virology*, **2007**, 81, 11170-8	6.6	48
75	Probing the receptor interactions of an H5 avian influenza virus using a baculovirus expression system and functionalised poly(acrylic acid) ligands. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 4038-47	3.4	11
74	Generation of candidate human influenza vaccine strains in cell culture - rehearsing the European response to an H7N1 pandemic threat. *Influenza and Other Respiratory Viruses*, **2007**, 1, 157-66	5.6	28
73	The Development of a Reverse Genetics System Enabling the Rescue of Recombinant Avian Influenza Virus, A/turkey/england/50-92/91 (H5N1). *Avian Diseases Digest*, **2007**, 2, e46-e46		2
72	NS1 proteins of avian influenza A viruses can act as antagonists of the human alpha/beta interferon response. *Journal of Virology*, **2007**, 81, 2318-27	6.6	69
71	Infection of human airway epithelium by human and avian strains of influenza a virus. *Journal of Virology*, **2006**, 80, 8060-8	6.6	193

70	Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host. *Journal of Antimicrobial Chemotherapy*, **2004**, 53, 759-65	5.1	38
69	Restrictions to the adaptation of influenza a virus h5 hemagglutinin to the human host. *Journal of Virology*, **2004**, 78, 502-7	6.6	54
68	The M1 matrix protein controls the filamentous phenotype of influenza A virus. *Virology*, **2004**, 321, 144-53	3.8	125
67	Attenuating mutations in the influenza virus genome which may increase the safety of vaccine production. *International Congress Series*, **2004**, 1263, 687-690		
66	A reverse genetics approach for recovery of recombinant influenza B viruses entirely from cDNA. *Journal of Virology*, **2002**, 76, 11744-7	6.6	62
65	The time course of the humoral immune response to rhinovirus infection. *Epidemiology and Infection*, **1989**, 103, 659-69	4.3	70
64	Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge		9
63	REACT-1 round 15 final report: Increased breakthrough SARS-CoV-2 infections among adults who had received two doses of vaccine, but booster doses and first doses in children are providing important protection		3
62	Rapid increase in Omicron infections in England during December 2021: REACT-1 study		2
61	Neutralising antibody activity against SARS-CoV-2 variants, including Omicron, in an elderly cohort vaccinated with BNT162b2		6
60	SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19		31
59	REACT-1 round 15 interim report: High and rising prevalence of SARS-CoV-2 infection in England from end of September 2021 followed by a fall in late October 2021		1
58	Favipiravir-resistant influenza A virus shows potential for transmission		1
57	SARS-CoV-2 variants of concern Alpha, Beta, Gamma and Delta have extended ACE2 receptor host-ranges		3
56	Behavioural responses to SARS-CoV-2 antibody testing in England: REACT-2 study. *Wellcome Open Research*,6, 203	4.8	
55	The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry		55
54	The Dynamics of Humoral Immune Responses Following SARS-CoV-2 Infection and the Potential for Reinfection		20
53	REACT-1 study round 14: High and increasing prevalence of SARS-CoV-2 infection among school-aged children during September 2021 and vaccine effectiveness against infection in England		6

52	Swine ANP32A supports avian influenza virus polymerase	3
51	A rare variant in ANP32B impairs influenza virus replication in human cells	2
50	A handheld point-of-care system for rapid detection of SARS-CoV-2 in under 20 minutes	5
49	Community prevalence of SARS-CoV-2 virus in England during May 2020: REACT study	31
48	Transient dynamics of SARS-CoV-2 as England exited national lockdown	6
47	Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults	98
46	CovidNudge: diagnostic accuracy of a novel lab-free point-of-care diagnostic for SARS-CoV-2	1
45	Mammalian ANP32A and ANP32B proteins drive alternative avian influenza virus polymerase adaptations	3
44	Resurgence of SARS-CoV-2 in England: detection by community antigen surveillance	10
43	High prevalence of SARS-CoV-2 swab positivity in England during September 2020: interim report of round 5 of REACT-1 study	8
42	The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission due to enhanced replication in airway cells	43
41	High and increasing prevalence of SARS-CoV-2 swab positivity in England during end September beginning October 2020: REACT-1 round 5 updated report	7
40	Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults	67
39	High prevalence of SARS-CoV-2 swab positivity and increasing R number in England during October 2020: REACT-1 round 6 interim report	19
38	Resistance of endothelial cells to SARS-CoV-2 infection in vitro	15
37	REACT-1 round 6 updated report: high prevalence of SARS-CoV-2 swab positivity with reduced rate of growth in England at the start of November 2020	11
36	REACT-1 round 7 interim report: fall in prevalence of swab-positivity in England during national lockdown	4
35	REACT-1 round 7 updated report: regional heterogeneity in changes in prevalence of SARS-CoV-2 infection during the second national COVID-19 lockdown in England	10

34	Determining the Mutation Bias of Favipiravir in Influenza Using Next-generation Sequencing		2
33	Avian ANP32B does not support influenza A virus polymerase and influenza A virus relies exclusively on ANP32A in chicken cells		1
32	A common TMPRSS2 variant protects against severe COVID-19		2
31	REACT-1 round 9 final report: Continued but slowing decline of prevalence of SARS-CoV-2 during national lockdown in England in February 2021		8
30	REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England		24
29	REACT-1 round 10 report: Level prevalence of SARS-CoV-2 swab-positivity in England during third national lockdown in March 2021		4
28	Ultrastructural insight into SARS-CoV-2 attachment, entry and budding in human airway epithelium		3
27	SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough		62
26	REACT-1 round 11 report: low prevalence of SARS-CoV-2 infection in the community prior to the third step of the English roadmap out of lockdown		3
25	The SARS-CoV-2 variants associated with infections in India, B.1.617, show enhanced spike cleavage by furin		40
24	SARS-CoV-2 lineage dynamics in England from January to March 2021 inferred from representative community samples		7
23	Acceptability, usability and performance of lateral flow immunoassay tests for SARS-CoV-2 antibodies: REACT-2 study of self-testing in non-healthcare key workers		1
22	Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination		24
21	REACT-1 round 12 report: resurgence of SARS-CoV-2 infections in England associated with increased frequency of the Delta variant		15
20	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 Beta (B.1.351) and other variants of concern in preclinical studies		8
19	Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study		3
18	SARS-CoV-2 Antibody Lateral Flow Assay for antibody prevalence studies following vaccine roll out: a Diagnostic Accuracy Study		1
17	A Common TMPRSS2 Variant Protects Against Severe COVID-19. *SSRN Electronic Journal*,	1	1

16	Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative advantage in primary airway cells or antibody escape		45
15	REACT-1 round 9 interim report: downward trend of SARS-CoV-2 in England in February 2021 but still at high prevalence		5
14	REACT-1 round 13 interim report: acceleration of SARS-CoV-2 Delta epidemic in the community in England during late June and early July 2021		2
13	Increasing SARS-CoV-2 antibody prevalence in England at the start of the second wave: REACT-2 Round 4 cross-sectional study in 160,000 adults		1
12	Behavioural responses to SARS-CoV-2 antibody testing in England: REACT-2 study. *Wellcome Open Research*,6, 203	4.8	
11	Mutations that adapt SARS-CoV-2 to mustelid hosts do not increase fitness in the human airway		2
10	REACT-1 round 13 final report: exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant in England during May to July 2021		21
9	REACT-1 round 8 interim report: SARS-CoV-2 prevalence during the initial stages of the third national lockdown in England		6
8	REACT-1 round 8 final report: high average prevalence with regional heterogeneity of trends in SARS-CoV-2 infection in the community in England during January 2021		7
7	Characterising the persistence of RT-PCR positivity and incidence in a community survey of SARS-CoV-2. *Wellcome Open Research*,7, 102	4.8	0
6	The Omicron SARS-CoV-2 epidemic in England during February 2022		2
5	The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK		2
4	SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2		4
3	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study. *Wellcome Open Research*,6, 358	4.8	0
2	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study. *Wellcome Open Research*,6, 358	4.8	0
1	An early warning system for emerging SARS-CoV-2 variants. *Nature Medicine*,	50.5	2